null

BCL2 Recombinant Monoclonal Antibody (RACO0592)

SKU:
RACO0592
Product Type:
Antibody
Reactivity:
Human, Mouse, Rat
Clonality:
Monoclonal
Target:
BCL2
  • BCL2 Recombinant Monoclonal Antibody (RACO0592)
  • BCL2 Recombinant Monoclonal Antibody (RACO0592)
  • BCL2 Recombinant Monoclonal Antibody (RACO0592)
  • BCL2 Recombinant Monoclonal Antibody (RACO0592)
$479 - $779
Frequently bought together:

Description

BCL2 Recombinant Monoclonal Antibody (RACO0592)

The BCL2 Recombinant Monoclonal Antibody (RACO0592) is a powerful tool for researchers studying BCL2, a key regulator of apoptosis and cell survival. This antibody, developed using recombinant technology, offers high specificity and sensitivity for detecting BCL2 protein in various cell types. It is validated for use in applications such as Western blotting, immunofluorescence, and immunohistochemistry.BCL2 is a critical protein in the regulation of programmed cell death, with important implications in cancer and other diseases.

By targeting BCL2, researchers can gain insights into the mechanisms of cell survival and death, as well as potential therapeutic strategies for cancer treatment. The BCL2 Recombinant Monoclonal Antibody provides a reliable tool for studying BCL2 expression and function, making it an essential component in cancer research and drug development efforts.

Product Name: BCL2 Recombinant Monoclonal Antibody
SKU: RACO0592
Size: 50uL, 100uL
UniProt No: P10415
Target Names: BCL2
Alternative Names: BCL2; Apoptosis regulator Bcl-2
Species Reactivity: Human, Mouse, Rat
Immunogen: A synthesized peptide
Immunogen Species: Homo sapiens (Human)
Clonality: Monoclonal
Purification Method: Affinity-chromatography
Conjugate: Non-conjugated
Form: Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time: Basically, we can dispatch the products out in 7-10 working days after receiving your orders. Delivery time may differ depending on the purchasing method or location. Please consult your local distributors for specific delivery times.
Tested Applications: ELISA WB IHC FC
Recommended Dilution:
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:500
Description:

The production of the BCL2 recombinant monoclonal antibody involves the utilization of protein technology and DNA recombinant techniques. In this process, animals are initially immunized with a synthesized peptide derived from human BCL2, and B cells are extracted from the immunized mice. From these B cells, positive ones are isolated and subjected to single clone identification. The genes responsible for the light and heavy chains of the BCL2 antibody are then amplified using PCR and incorporated into a plasmid vector. This recombinant vector is subsequently introduced into host cells for antibody expression. Through affinity chromatography, the BCL2 recombinant monoclonal antibody is purified from the supernatant of the cell culture. Rigorous validation ensures the reliability and applicability of the antibody in various experimental techniques, including ELISA, WB, IHC, and FC. This antibody is designed to specifically target the Bcl-2 protein in human, mouse, and rat species.
Function: Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function. May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release.
Gene References into Functions:
  1. long noncoding RNA HOTAIR suppresses TNF-alpha induced nucleus pulposus cell apoptosis by regulating miR-34a/Bcl-2 axis. PMID: 30138895
  2. The mitochondrial depolarization also stems from the Bcl-2 inhibition mediated by DFMT, followed by the cytochrome c release that activates caspase signaling. With the participation of the two-pronged mechanism, a programmed apoptosis is induced in response to DFMT treatment. PMID: 28805013
  3. miR-7-5p reduced energy consumption via inhibiting PARP-1 expression, and miR-7-5p increased energy generation by suppressing the expression of Bcl-2. PMID: 30219819
  4. Venetoclax-based combination treatment for newly diagnosed elderly patients for whom intense chemotherapy is not an option may be the first setting in which this agent may be employed in Acute myeloid leukemia. Based on pre-clinical evidence, BCL-2 inhibition may be useful in relapsed/refractory disease in conjunction with cytotoxic therapy, but has modest single agent activity. PMID: 29264938
  5. Glandular, menopause-independent DFF40, DFF45, and Bcl-2 overexpression may play an important role in the pathogenesis of endometrial polyps and benign endometrial hyperplasia PMID: 28914671
  6. data strongly suggest that XIAP-mediated inhibition of final caspase-3 processing is the last and major hurdle in TRAIL-induced apoptosis in NCI-H460 cells, which can be overcome by Smac in a Bcl-2 level dependent manner. PMID: 29927992
  7. could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in classical Hodgkin lymphoma PMID: 29708579
  8. Fluorescence in situ hybridization studies (histologic sections) confirmed translocations of MYC (8q24), BCL2 (18q21) and BCL6 (3q27) in all patients. PMID: 30043475
  9. High BCL-2 expression is associated with colorectal cancer. PMID: 30015962
  10. MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression. PMID: 29914005
  11. Results revealed that BCL-2 protein is highly expressed in colon cancer tissues and was identified as a direct target for mir-184. BCL-2 appeared to participate in cell cycle regulation and malignant transformation to colon cancer. PMID: 28782841
  12. Results indicate that full-length B-cell leukemia 2 family protein (Bcl-2) Ile14Gly/Val15Gly displayed severely reduced structural stability and a shortened protein half-life. PMID: 29131545
  13. Data show the regulation of BCL2 mainly associated with methylation across the molecular subtypes of breast cancer. Luminal A and B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with better prognosis than downregulation of BCL2. PMID: 28701032
  14. c-MYC/BCL2 protein co-expression in non-germinal center B-cell subtype constituted a unique group with extremely inferior outcome regardless of ethnicity PMID: 29801406
  15. Overexpression of LIN28B promotes colon cancer development by increasing BCL-2 expression. PMID: 29669301
  16. High BCL2 expression is associated with Prostate Cancer. PMID: 29641255
  17. The findings of the present study indicated that icariin prevented injury and apoptosis in HUVECs following oxLDL treatment, in particular via the regulation of protein and mRNA expression levels of Bcl-2 and caspase-3. PMID: 29532884
  18. BCL2 expression is also a strong predictive marker for DLBCL patients treated with R-CHOP. PMID: 28154089
  19. High BCL2 expression is associated with drug resistance in ovarian cancer. PMID: 29286126
  20. Elevated expression of Bcl-2 was an independent prognostic factor for poorer overall survival in triple-negative breast cancer and as such a significant marker for tumor aggressiveness. PMID: 28777433
  21. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression. PMID: 29666157
  22. Phosphorylated and activated deoxycytidine kinase inhibits ionizing radiation (IR)-induced total cell death and apoptosis, and promotes IR-induced autophagy through the mTOR pathway and by inhibiting the binding of Bcl2 protein to BECN1 in breast cancer cells. PMID: 29393406
  23. It was demonstrated that hypoxia stimulates migration and invasion in the MG63 human osteosarcoma cell line, which was correlated with the downregulation of miR15a and upregulation of B-cell lymphoma 2 (Bcl2) expression PMID: 29484432
  24. miR-21 may promote salivary adenoid cystic carcinoma progression via PDCD4 and PTEN down-regulation and Bcl-2 up-regulation. PMID: 29328455
  25. Paper analyses results of serum cytokines and lymphocyte apoptosis study in nodular goiter against the background of autoimmune thyroiditis and thyroid adenoma based on the cell preparedness to apoptosis, the number of apoptotic lymphocytes and the content of proapoptotic tumor necrosis factor-alpha, interleukins in serum, considering the polymorphism of BCL-2, CTLA-4 and APO-1 genes. PMID: 29250672
  26. Permeabilisation of the mitochondrial outer membrane (MOMP) is directly regulated by the BCL-2 (B cell lymphoma 2) family in mammals [Review]. PMID: 28396106
  27. The present study demonstrated that TATfused inositol 1,4,5trisphosphate receptorderived peptide (TATIDPS), which targets the BH4 domain of Bcl2, increased cisplatininduced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. PMID: 29207009
  28. we highlight the emerging recognition of MYC and BCL2 coexpression as the most robust predictor of diffuse large B cell lymphoma outcome, and discuss rationally conceived experimental approaches to treat these high-risk patients. PMID: 29198442
  29. Bcl-2 binding to ARTS involves the BH3 domain of Bcl-2. Lysine 17 in Bcl-2 serves as the main acceptor for ubiquitylation, and a Bcl-2 K17A mutant has increased stability and is more potent in protection against apoptosis. PMID: 29020630
  30. The expression levels of miR-204-5p were downregulated in prostate cancer cells compared with normal prostate epithelial cells. BCL2 mRNA and protein expression decreased in miR-204-5p-transfected cells, which led to cytochrome C release from mitochondria. Cotransfection of a reporter vector harboring the BCL2 3'-untranslated region to compete with endogenous transcripts partially rescued miR-204-5p-induced apoptosis. PMID: 27519795
  31. GATA4 was a transcription factor that activated mouse double minute 2 homolog (MDM2) and B cell lymphoma 2 (BCL2) expression in ALL cells. PMID: 28849107
  32. High BCL2 expression is associated with oncogenicity and chemoresistance in hepatocellular carcinoma. PMID: 28445151
  33. Gastrin and BCL2 apoptosis regulator (Bcl2) are highly expressed in gastric cancer tissues, and they are correlated with the clinicopathologic features. PMID: 29268861
  34. This study utilized a lentiviral vector that overexpressed the human VEGF and Bcl-2 genes simultaneously. Co-overexpression of VEGF and Bcl-2 inhibits the oxygen glucose deprivation induced apoptosis of mesenchymal stem cells. PMID: 28627637
  35. Double-hit lymphoma (DHL) is an aggressive form of DLBCL with an unmet treatment need, in which MYC rearrangement is present with either BCL2 or BCL6 rearrangement PMID: 28952038
  36. The expression of Bcl-2 and E cadherin immunopositivity was associated positively with tumor grade, high T category and histopathological grades. The results of this study points to the significance of cell proliferation and invasion as a major determinant of prognosis in OSCC. PMID: 28393810
  37. meta-analysis suggests a role BCL-2 promoter polymorphisms in cancer susceptibility and prognosis; rs2279115 was associated with higher risk of cancer susceptibility in Asia but not in Caucasian; rs2279115 was associated with a higher risk in digestive system cancer and endocrine system cancer but not breast cancer, respiratory cancer and hematopoietic cancer PMID: 28445963
  38. In this study, we investigated whether APG-1252-12A inhibits the growth of five leukemia cell lines in a concentration- or time-dependent manner by MTS assay.APG-1252-12A is a Bcl-2 homology (BH)-3 mimetic that specifically binds to Bcl-2 and Bcl-xl, which has shown efficacy in some Bcl-2 dependent hematological cancers PMID: 28586007
  39. Multiple lines of evidence suggest formation of a potential cruciform DNA structure at MBR peak III, which was also supported by in silico studies. The formation of a non-B DNA structure could be a basis for fragility at BCL2 breakpoint regions, eventually leading to chromosomal translocations. PMID: 29246583
  40. The upregulation of miR-219-5p inhibited melanoma growth and metastasis and strengthened melanoma cells chemosensitivity by targeting Bcl-2. Therefore, the modulation of miR-219-5p expression may be a novel treatment strategy in melanoma. PMID: 28884131
  41. The expression of the anti-apoptotic protein Bcl-2 was greater in luminal A breast cancer tissue samples compared to triple-negative breast cancer. PMID: 28801774
  42. Lnc_ASNR interacted with the protein ARE/poly (U)-binding/degradation factor 1(AUF1), which is reported to promote rapid degradation of the Bcl-2 mRNA, an inhibitor of apoptosis. Lnc_ASNR binds to AUFI in nucleus, decreasing the cytoplasmic proportion of AUF1 which targets the B-cell lymphoma-2 (Bcl-2) mRNA. PMID: 27578251
  43. Bcl-2 high expression was significantly correlated with favorable overall survival and better disease/recurrence free survival in colorectal cancer.[meta-analysis] PMID: 28785155
  44. High expression of bcl-2 in KCOT supports the general agreement that some features of KCOT are those of a neoplasia. The bcl-2 expression in connective tissue cells suggests that these cells may also be important as epithelial cells in the biological behavior odontogenic keratocyst PMID: 28862228
  45. Results identified BCL2 as a direct target of miR-139-5p in colorectal cancer cells and showed that the tumor suppressor activity of miR-139-5p is mediated by the modulation of BCL2 expression. PMID: 27244080
  46. Polo-like kinase inhibition can sensitize cholangiocarcinoma cells to cisplatin-induced apoptosis with proteasomal Bcl-2 degradation as an additional pro-apoptotic effect. PMID: 28652654
  47. Lipid oxidation product 4-hydroxy-2-nonenal is at the crossroads of NF-kappaB pathway and anti-apoptotic Bcl2 expression. (Review) PMID: 27840321
  48. Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199, a BCL-2 inhibitor. Consistently, clinical samples from ABC-DLBCL patients who experienced poorer response to ibrutinib had higher BCL2 gene expression. We further demonstrated synergistic growth suppression by ibrutinib and ABT-199 in multiple ABC-DLBCL, GCB-DLBCL, and follicular lymphoma cell lines. PMID: 28428442
  49. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors PMID: 27217294
  50. The BCL2 c.-938C>A and c.21G>A single-nucleotide polymorphisms showed a significant impact on outcome with transitional cell carcinoma of the bladder PMID: 28417194
Subcellular Location: Mitochondrion outer membrane; Single-pass membrane protein. Nucleus membrane; Single-pass membrane protein. Endoplasmic reticulum membrane; Single-pass membrane protein.
Protein Families: Bcl-2 family
Tissue Specificity: Expressed in a variety of tissues.
Database Links:

HGNC: 990

OMIM: 151430

KEGG: hsa:596

STRING: 9606.ENSP00000329623

UniGene: Hs.150749
Product Image Western Blot
Positive WB detected in: HepG2 whole cell lysate, Jurkat whole cell lysate, MCF-7 whole cell lysate
All lanes: BCL2 antibody at 1μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 26 KDa
Observed band size: 26 KDa
Product Image IHC image diluted at 1:100 and staining in paraffin-embedded human thyroid tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Product Image IHC image diluted at 1:100 and staining in paraffin-embedded human lymph node tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Product Image Overlay histogram showing Jurkat cells stained with CSB-RA002611A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then permeabilized with 0.3% Triton X-100 for 2 min.The cells were then incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4℃.The secondary antibody used was FITC goat anti-rabbit IgG (H+L) at 1/200 dilution for 1 h at 4℃. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

Related Products